NEW

Getinge Announces Medical Device Recall

Getinge has announced a global medical device recall related to specific Sevoflurane vaporizers for Flow Family Anesthesia systems. To date, no patient or operator adverse events have been reported. Getinge has reported to relevant authorities according to applicable...

Research: Medical Instrument Processing Personnel May Be Exposed to Tissue, Blood and Patient Fluids Despite PPE

“This pilot documented substantial splashing and droplet dispersal during manual cleaning of medical instruments, and personnel got wet even though they were wearing all the recommended PPE,”

New Scrubs Made of Bacteria-Killing Textile

Livinguard, a Swiss-based leader in self-disinfecting hygiene technology, has launched an apparel line of permanent self-disinfecting scrubs, underscrubs and lab coats utilizing its EPA-registered bacteria-killing textile. Livinguard scrubs, that continuously...

Finnish Startup Surgify Shares New Bone Cutting Technology

Finnish startup Surgify – that recently launched an all-new and innovative surgical technology that allows surgeons to perform surgical operations on bones faster and safer – has seen its first use cases on patients, according to a news release. The first surgeries...

MITA Comments on CMS Proposed Rescission of MCIT Program

Medical Imaging & Technology Alliance (MITA)

The Medical Imaging & Technology Alliance (MITA) in a comment letter to Centers for Medicare & Medicaid Services (CMS), expressed disappointment with the agency’s proposal to withdraw the previously finalized Medicare Coverage of Innovative Technology (MCIT) rule and urged CMS to work with industry, health care providers, patients and others to improve and expedite the path from U.S. Food & Drug Administration (FDA) marketing authorization to CMS coverage.

“Medical technology developers need to have access to expedient, transparent, and predictable pathways to bring innovative products to Medicare beneficiaries,” the letter noted. It continued by highlighting MITA comments requesting that the MCIT program be expanded beyond just “Breakthrough” technologies, given that not all innovative products earn this designation.

In January 2021, CMS published a final rule called The Medicare Coverage of Innovative Technology and Definition of ‘Reasonable and Necessary’ (MCIT/R&N). The MCIT program would have granted expedited Medicare coverage for up to four years for any FDA-designated “Breakthrough” device once the device received marketing authorization.

The full MITA comments are available here.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X